Trial record 2 of 2 for:    mab114

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03719586
Recruitment Status : Recruiting
First Posted : October 25, 2018
Last Update Posted : December 17, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:


Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give. They need to test the drugs and compare them in a controlled way. Researchers want to test 3 drugs with people who have Ebola and are in treatment centers.


To study the safety and effectiveness of 3 drugs for people with Ebola virus.


People of any age with Ebola infection who are in treatment centers


Participants will be screened with questions, medical history, and blood tests.

Participants will be randomly assigned to get 1 of 3 study drugs:

  • ZMapp by IV over about 4 hours. It will be given 3 times, 3 days apart.
  • Remdesivir by IV over about 1 hour. It will be given once a day for 10 days.
  • Mab114 by IV for 30-60 minutes. It will be given 1 time.

For at least a week, participants will stay in isolation in a clinic. They will:

  • Get supportive care and be monitored
  • Have a small plastic tube (IV) put in an arm vein for several days to give fluids and collect blood.
  • Get their study drug.
  • Be monitored for disease signs and drug side effects. They may get medicines for side effects.
  • Have blood and urine tests.

Participants will stay in the clinic until they finish the study drug and are well enough to leave.

Participants will have 2 follow-up visits over 2 months. They will answer questions and give blood and semen samples.

Condition or disease Intervention/treatment Phase
Ebola Virus Drug: ZMapp Drug: Remdesivir Drug: MAb114 Phase 2

Detailed Description:

Species Zaire ebolaviruses (EBOV) are members of the Filoviridae and are known primarily as the underlying cause of severe viral hemorrhagic fevers with disturbingly high case fatality rates. Between 1994 and the present, there have been many filovirus outbreaks affecting mostly central Africa, with 2 large outbreaks in 1995 in Kikwit, Democratic Republic of Congo (DRC), and in Gulu, Uganda in 2000-2001. The 2013-2016 West African outbreak significantly exceeded all previous outbreaks in geographic range, number of patients affected, and in disruption of typical activities of civil society. In 2018 there have been two additional outbreaks of EBOV infection, both in the Democratic Republic of the Congo and constituting the 9th and 10th recorded outbreaks of this infection in that country. The 10th outbreak is currently ongoing in the DRC as of September 2018 and has raised great concern because of the potential to expand greatly in scope and to spread to surrounding regions.

It has been suggested that one of the most important elements necessary to improve survival from Ebola virus infection is the provision of supportive care inclusive of hemodynamic support in the form of aggressive fluid replacement, ability to diagnose and correct severe metabolic derangements, early treatment of sepsis, and other standards of modern medical care. A small number of investigational therapeutics have been developed as putative antiviral strategies for treating this infection. Unfortunately, phase 1/2 data supporting the safety and efficacy of these agents are often scant, and thus there remains some degree of equipoise as to which of these interventions should be prioritized in the treatment of severe infection. The triple monoclonal antibody product ZMapp was studied through a randomized controlled trial (RCT) in the 2014-2016 West African outbreak and remains perhaps the best characterized of the available investigational products, but the end of that outbreak forced the RCT to close prior to crossing pre-specified evidentiary boundaries.

A WHO Research and Development Ebola Therapeutics Committee agreed that, given the lethality of Ebola virus and the combination of human and non-human primate (NHP) efficacy data for ZMapp, there should be two options for the control arm: either ZMapp+oSOC or oSOC alone. The decision about the appropriate control arm will be at the discretion of the host country. The DRC has chosen to use ZMapp + oSOC.

This multicenter, multi-outbreak, randomized controlled trial will study the comparative safety and efficacy of two additional investigational therapeutics compared to ZMapp in patients with known EBOV disease. The primary endpoint of this trial will be mortality by Day 28, with a number of secondary endpoints that will generate knowledge about the safety, ease of administration, and antiviral activity of these adjunctive interventions.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients With Ebola Virus Disease
Estimated Study Start Date : December 20, 2018
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : November 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola
Drug Information available for: Coal Tar

Arm Intervention/treatment
Experimental: Control
Zmapp plus optimized Standard of Care (oSOC)
Drug: ZMapp
Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1.

Experimental: A
Remdesivir plus optimized Standard of Care (oSOC)
Drug: Remdesivir
Loading Dose on Day 1 followed by 9 days of maintenance dosing on Days 2 to 10,administered intravenously.

Experimental: B
MAb114 plus optimized Standard of Care (oSOC)
Drug: MAb114
50 mg/kg of body weight administered intravenously on Day 1 as a single infusion.

Primary Outcome Measures :
  1. Mortality [ Time Frame: Through 28 days ]

Secondary Outcome Measures :
  1. Time to first negative Ebola virus RT-PCR [ Time Frame: Throughout ]
  2. Viremia [ Time Frame: Days 1, 2, 3, 4, 6, 8, 10, 14, and 28. ]
  3. Incidence of AE/SAEs [ Time Frame: Throughout ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Males or females of any age with documented positive RT-PCR for acute Ebola virus infection within 3 days prior to enrollment and who have symptoms of any duration.
  • Willingness of study participant to accept randomization to any assigned treatment arm.
  • All males and females of childbearing potential must be willing to use effective methods of contraception, from time of enrollment until Day 58 of study.
  • Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.
  • Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so.


  • Patients who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of this protocol through Day 28.
  • Prior treatment with any investigational antiviral drug therapy against Ebola virus infection within 5 half-lives or 30 days, whichever is longer, prior to enrollment. (Patients who have received an experimental (or, in future, potentially a licensed) immunization against Ebola virus remain eligible.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03719586

Contact: Richard T Davey, M.D. (301) 496-8029

United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Congo, The Democratic Republic of the
Ebola Treatment Centers throughout the DRC Recruiting
Kinshasa Gombe, Congo, The Democratic Republic of the
Contact: Jean-Jacques Muyembe-Tamfum, MD, PhD    243898949289   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Richard T Davey, M.D. National Institute of Allergy and Infectious Diseases (NIAID)

Additional Information:
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463.

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID) Identifier: NCT03719586     History of Changes
Other Study ID Numbers: 190003
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: December 17, 2018
Last Verified: November 28, 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Viral Hemorrhagic Fever
Ebola Treatment Center
Zaire Ebola Virus

Additional relevant MeSH terms:
Hemorrhagic Fever, Ebola
Virus Diseases
Hemorrhagic Fevers, Viral
RNA Virus Infections
Filoviridae Infections
Mononegavirales Infections
Coal Tar
Keratolytic Agents
Dermatologic Agents